The proposed biosimilar references Genentech’s Pulmozyme, a biologic first approved in the early 1990s in both the European Union and the United States. Pulmozyme is used in conjunction with other therapies to improve pulmonary function in patients with cystic fibrosis.
JHL Biotech has announced that the Dutch Healthcare Authority has approved a clinical trial application for the company’s proposed biosimilar of the cystic fibrosis drug dornase alfa. JHL will begin the phase 1 clinical trial of JHL1922 in the Netherlands beginning this month, March 2018.
The proposed biosimilar references Genentech’s Pulmozyme, a biologic first approved in the early 1990s in both the European Union and the United States. Pulmozyme is used in conjunction with other therapies to improve pulmonary function in patients with cystic fibrosis. A recombinant human deoxyribonuclease 1 enzyme that selectively treats cystic fibrosis based on genetic markers, dornase alfa has also been shown to reduce the risk of respiratory tract infections that require parenteral antibiotics. The biologic is administered daily using a rapid nebulizer system or a jet nebulizer connected to an air compressor.
If JHL1922 is eventually approved, a cheaper biosimilar could expand access to dornase alfa treatment for the approximately 100,000 patients with cystic fibrosis worldwide. According to JHL’s own estimates, the annual cost of Pulmozyme per patient ranges from $12,000 to $40,000.
However, just as a potential biosimilar nears for this drug that has become a mainstay in treating the symptoms of cystic fibrosis, newer therapies that target the underlying cause of the disease are reaching the market; drug maker Vertex announced in February that the FDA had approved its tezacaftor/ivacaftor and ivacaftor combination (Symdeko) in patients with at least 1 genetic mutation that is responsive to tezacaftor plus ivacaftor. The newly approved drug addresses the trafficking and processing defect of a gene that causes cystic fibrosis.
While the therapy offers a new treatment option for patients, it comes as a cost far higher than that of dornase alfa; Vertex’s drug carries a list price of $292,000 per patient per year. Vertex is also the sponsor of other high-cost cystic fibrosis therapies, including the $311,000-per-patient-per-year ivacaftor (Kalydeco), and multiple investigational drugs currently in phase 3 studies.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.